

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Pegcetacoplan for treating geographic atrophy [ID4041]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
In response to consultation, consultees noted there could be potential that having pegcetacoplan could present issues for accessibility. <ul style="list-style-type: none">• Pegcetacoplan treatment will be in hospital and will disadvantage those less able to be supported to travel to appointments and might disadvantage those in rural and more remote areas.• People may not take up treatment or be able to sustain the treatment regime for the duration required.• It was also noted that people with geographic atrophy are likely to have some vision loss already. This may impact on their ability to manage interactions with healthcare services.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Access to treatment is not an equality issue that NICE can address in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope have been made to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues have been identified during the scoping process.

Approved by Associate Director (name): Ross Dent

Date: 10/08/2023